【今回のトピックス】
ASCO Annual Meeting 2017
-Making a Difference in Cancer Care with You-
今回のSynix Oncology Newsletterでは、SynixとOracle Life Sciencesが注目するASCO 2017のKey Topicをお届けします。
ASCO 2017の開催が近づいて参りました。 (米国 / シカゴにて6月2日～6日まで開催）
今年のテーマは「Making a Difference in Cancer Care With You （ともにがんケアの変革を）」。5月17日にAbstractも発表され、5,000以上の研究が発表される予定です。
ASCO出発に先駆けて、Synix とOracle Life Sciencesでピックアップした注目の発表を幾つかご紹介します。学会開催中は会場をOracle Life Sciencesの約25名のコンサルタントとともに情報収集に走りまわる予定です。会場で見かけられました際には、ぜひお気軽にお声をかけていただけますと幸いです。
ASCO 注目トピックス
Abstract LBA500 / Breast
(Monday June 5, 9:45 AM to 12:45 PM at Hall D2)
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).
Abstract LBA4 Plenary / Breast
(Sunday June 4, 1:00 PM to 4:00 PM at Hall B1)OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
Abstract 1000 / Breast
(Saturday June 3, 1:15 PM to 4:15 PM at Hall D1)MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy.
Abstract 7504 / CLL
(Saturday June 3, 3:00 PM to 6:00 PM at S100bc)Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.
Abstract 7002 / CML
(Tuesday June 6, 9:45 AM to 12:45 PM at E450ab)Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.
Abstract 4001 / HCC
(Sunday June 4, 8:00 AM to 11:00 AM at Hall D2)Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Abstract 9500 / Melanoma
(Sunday June 4, 8:00 AM to 11:00 AM at Arie Crown Theater)A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
Abstract 7502 / NHL (Follicular)
(Saturday June 3, 3:00 PM to 6:00 PM at S100bc)Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
Abstract LBA9007 / NSCLC
(Tuesday June 6, 9:45 AM to 12:45 PM at Hall D1)Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
Abstract LBA9008 / NSCLC
(Tuesday June 6, 9:45 AM to 12:45 PM at Hall D1)Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
Abstract LBA3 Plenary / Prostate
(Sunday June 4, 1:00 PM to 4:00 PM at Hall B1)LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Abstract 4507 / RCC
(Monday June 5, 8:00 AM to 11:00 AM at Arie Crown Theater)Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).
Abstract 11000 / Sarcoma
(Friday June 2, 3:00 PM to 6:00 PM at S100bc)Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas.